Versor Investments LP Takes $665,000 Position in Masimo Co. (NASDAQ:MASI)

Versor Investments LP purchased a new stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,278 shares of the medical equipment provider's stock, valued at approximately $665,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MASI. Vanguard Group Inc. grew its position in Masimo by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider's stock worth $560,421,000 after acquiring an additional 26,473 shares in the last quarter. Capital Research Global Investors lifted its stake in Masimo by 6.4% in the fourth quarter. Capital Research Global Investors now owns 2,269,189 shares of the medical equipment provider's stock worth $265,972,000 after purchasing an additional 136,617 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Masimo by 6.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,607,310 shares of the medical equipment provider's stock valued at $188,393,000 after buying an additional 93,861 shares during the period. Farallon Capital Management LLC grew its stake in shares of Masimo by 13.6% during the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider's stock valued at $218,742,000 after buying an additional 177,914 shares during the last quarter. Finally, Schroder Investment Management Group raised its holdings in shares of Masimo by 59.6% in the fourth quarter. Schroder Investment Management Group now owns 877,539 shares of the medical equipment provider's stock worth $102,856,000 after buying an additional 327,863 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on MASI shares. Piper Sandler lifted their target price on Masimo from $160.00 to $165.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Wednesday, August 7th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $144.67.

Masimo Stock Up 0.9 %

NASDAQ:MASI traded up $1.03 during mid-day trading on Wednesday, reaching $115.05. The company's stock had a trading volume of 306,434 shares, compared to its average volume of 651,791. Masimo Co. has a 1 year low of $75.22 and a 1 year high of $153.93. The stock has a fifty day moving average of $115.58 and a 200-day moving average of $126.44. The firm has a market capitalization of $6.12 billion, a PE ratio of 78.45 and a beta of 0.97. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The company had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. During the same period in the prior year, the firm earned $0.62 earnings per share. The firm's revenue for the quarter was up 9.0% compared to the same quarter last year. Equities research analysts forecast that Masimo Co. will post 3.87 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.